Decipher Labs Ltd Stock Price Today (NSE: DECIPHER)
Fundamental Score
Decipher Labs Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Decipher Labs Ltd share price today is ₹7.50, down 0.66% on NSE/BSE as of 23 June 2026. Decipher Labs Ltd (DECIPHER) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹10.41 (Cr). The 52-week high for DECIPHER share price is ₹11.95 and the 52-week low is ₹5.00. The company has a Return on Equity (ROE) of 1.16% and a debt-to-equity ratio of 0.02.
Decipher Labs Ltd Share Price Chart — NSE/BSE Historical Performance
Decipher Labs Ltd share price chart: -8.28% return over the past month. 52-week high ₹11.95, 52-week low ₹5.00.
Decipher Labs Ltd — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹7.50 | ₹7.50 | ₹7.50 | ₹7.50 | 2.51K (Cr) | |
| ₹7.55 | ₹7.55 | ₹7.55 | ₹7.55 | 3.35K (Cr) | |
| ₹7.10 | ₹7.55 | ₹7.10 | ₹7.55 | 5.17K (Cr) | |
| ₹7.19 | ₹7.20 | ₹7.19 | ₹7.20 | 477.00 (Cr) | |
| ₹7.36 | ₹7.36 | ₹7.30 | ₹7.30 | 13.50K (Cr) | |
| ₹7.17 | ₹7.17 | ₹7.02 | ₹7.02 | 6.69K (Cr) | |
| ₹7.42 | ₹7.42 | ₹7.06 | ₹7.20 | 1.52K (Cr) | |
| ₹7.13 | ₹7.45 | ₹7.13 | ₹7.42 | 700.00 (Cr) | |
| ₹7.10 | ₹7.13 | ₹7.10 | ₹7.13 | 1.73K (Cr) | |
| ₹7.13 | ₹7.13 | ₹7.13 | ₹7.13 | 1.67K (Cr) |
Decipher Labs Ltd — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹7.55 | ₹7.55 | ₹7.50 | ₹7.50 | -0.66% | |
| ₹8.00 | ₹8.00 | ₹7.02 | ₹7.55 | -5.63% | |
| ₹5.16 | ₹8.25 | ₹5.16 | ₹8.00 | +55.04% | |
| ₹5.93 | ₹6.84 | ₹5.00 | ₹5.00 | -15.68% | |
| ₹8.05 | ₹8.88 | ₹7.21 | ₹7.40 | -8.07% | |
| ₹10.90 | ₹10.90 | ₹7.50 | ₹7.80 | -28.44% | |
| ₹10.58 | ₹10.60 | ₹9.00 | ₹10.45 | -1.23% | |
| ₹9.24 | ₹10.99 | ₹9.00 | ₹9.99 | +8.12% | |
| ₹10.25 | ₹10.77 | ₹9.01 | ₹9.38 | -8.49% | |
| ₹10.33 | ₹11.20 | ₹10.00 | ₹10.47 | +1.36% | |
| ₹10.85 | ₹11.66 | ₹10.20 | ₹10.66 | -1.75% | |
| ₹11.50 | ₹11.95 | ₹10.53 | ₹10.85 | -5.65% |
AI Research Briefing
Powered by Gemini · 2026-04-10
Decipher Labs is a high-risk micro-cap turnaround story with a history of regulatory issues and weak financials, making it a likely value trap.
WHAT'S HAPPENING NOW (last 2-4 weeks)
Decipher Labs' share price is volatile. On April 9, 2026, it
WHAT IS DRIVING THE STOCK
Recent Price Momentum: The stock has shown a 1-week gain of +46.85% and a 1-month gain of +23.87%.
Low Valuation (Potentially Misleading): While P/E is negative, some sources suggest the stock isn't expensive based on historical averages, but this is unreliable given recent losses.
- Recent positive price momentum (1-week gain of +46.85%, 1-month gain of +23.87%)
- Low valuation based on some metrics, although P/E is negative
- Potential turnaround story if governance improves and profitability is achieved
- Significant order wins in either pharma or IT consultancy
- Successful resolution of past regulatory issues
- Consistent profitability in future quarters
- Micro/SME cap - liquidity risk
- History of regulatory issues (SEBI action in 2025)
- Weak financials: Q2 FY26 net profit plunged 101.50% YoY, revenue contracted 26.58%, negative operating cash flows
Zero institutional participation. Low promoter holding (16.43%) suggests limited confidence from those closest to the company.
The Indian pharmaceutical industry is projected to grow to $130 billion by 2030, but Decipher Labs faces significant company-specific challenges.
No. Negative operating cash flows.
The next 3-6 months will be crucial to see if Decipher Labs can stabilize its financials and demonstrate a path to sustainable profitability. Without significant improvement, the stock is likely to continue to struggle.
Primary Thesis Risk
Inability to achieve sustainable profitability and continued regulatory scrutiny will lead to permanent capital loss.
For educational purposes only. Not investment advice. Consult a SEBI-registered advisor before investing.
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Decipher Labs Ltd Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Decipher Labs Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of DECIPHER across key market metrics for learning purposes.
Positive Indicators
3 factors identified
Robust Profit Growth (101.50%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture.
Conservative Debt Levels (D/E: 0.02)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
9 factors identified
Below-Average Return on Equity (1.16%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
Suboptimal ROCE (-4.67%)
Observation: Returns on capital employed are below expectations.
Analysis: ROCE <10% suggests potential inefficiencies in capital allocation.
Margin Pressure Concerns (1.23%)
Observation: Operating margins are below industry standards.
Analysis: OPM <5% may indicate pricing pressures or cost management challenges.
Revenue Contraction (-26.58%)
Observation: Sales decline may indicate market challenges or competitive pressures.
Analysis: Negative revenue growth requires analysis of market conditions.
Limited Growth History (-1.18% CAGR)
Observation: Below-average 5-year sales growth trajectory.
Analysis: Low sales CAGR may indicate mature markets or limited growth opportunities.
Weak Earnings Growth (-25.06% CAGR)
Observation: Below-average 5-year EPS growth performance.
Analysis: Low EPS growth may not keep pace with inflation.
Stagnant Profit Growth (-25.06% CAGR)
Observation: Limited 5-year profit growth trajectory.
Analysis: Low profit growth may indicate scalability challenges or market maturity.
Low Promoter Commitment (16.43%)
Observation: Reduced promoter stake may indicate limited confidence.
Analysis: Low promoter holding may raise questions about management commitment.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
Decipher Labs Ltd vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare Decipher Labs Ltd with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
Decipher Labs LtdDecipher Labs L...Selected✓ DECIPHER • 524752 | 9/100 | ₹7.50₹8 | ₹10.41₹10.41 | — — | 1.16%Poor 1.16% Poor | -4.67%Poor -4.67% Poor | 0.02Excellent 0.0 Excellent | -25.06%Poor -25.06% Poor | -1.18%Poor -1.18% Poor | 0.00% |
Sun Pharmaceutical Industries LtdSun Pharmaceuti... SUNPHARMA • 524715 | 65.2/100 | ₹1796.50₹1797 | ₹433738.68₹433738.68 | 37.57Average 37.6 Average | 16.86%Good 16.86% Good | 20.21%Excellent 20.21% Excellent | 0.07Excellent 0.1 Excellent | 23.78%Excellent 23.78% Excellent | 9.87%Good 9.87% Good | 0.89% |
Divis Laboratories LtdDivis Laborator... DIVISLAB • 532488 | 67.9/100 | ₹6553.50₹6554 | ₹170445.88₹170445.88 | 68.59Average 68.6 Average | 15.35%Good 15.35% Good | 20.44%Excellent 20.44% Excellent | 0.01Excellent 0.0 Excellent | 10.41%Good 10.41% Good | 11.65%Good 11.65% Good | 0.47% |
Torrent Pharmaceuticals LtdTorrent Pharmac... TORNTPHARM • 500420 | 65.3/100 | ₹4350.40₹4350 | ₹126430.62₹126430.62 | 58.36Average 58.4 Average | 26.52%Excellent 26.52% Excellent | 27.05%Excellent 27.05% Excellent | 0.33Excellent 0.3 Excellent | 13.84%Good 13.84% Good | 7.72%Good 7.72% Good | 0.86% |
Cipla LtdCipla Ltd... CIPLA • 500087 | 59/100 | ₹1390.30₹1390 | ₹123059.76₹123059.76 | 22.62Average 22.6 Average | 17.77%Good 17.77% Good | 22.72%Excellent 22.72% Excellent | 0.01Excellent 0.0 Excellent | 28.68%Excellent 28.68% Excellent | 9.97%Good 9.97% Good | 0.85% |
Dr Reddys Laboratories LtdDr Reddys Labor... DRREDDY • 500124 | 59.2/100 | ₹1290.40₹1290 | ₹105224.96₹105224.96 | 18.23Average 18.2 Average | 17.96%Good 17.96% Good | 22.69%Excellent 22.69% Excellent | 0.16Excellent 0.2 Excellent | 22.28%Excellent 22.28% Excellent | 13.26%Good 13.26% Good | 0.63% |
Lupin LtdLupin Ltd... LUPIN • 500257 | 66.7/100 | ₹2262.90₹2263 | ₹95148.15₹95148.15 | 22.00Average 22.0 Average | 20.62%Excellent 20.62% Excellent | 21.30%Excellent 21.30% Excellent | 0.32Excellent 0.3 Excellent | 54.88%Excellent 54.88% Excellent | 8.11%Good 8.11% Good | 0.58% |
Zydus Lifesciences LtdZydus Lifescien... ZYDUSLIFE • 532321 | 68.7/100 | ₹1091.20₹1091 | ₹94253.78₹94253.78 | 18.74Average 18.7 Average | 21.21%Excellent 21.21% Excellent | 24.31%Excellent 24.31% Excellent | 0.38Excellent 0.4 Excellent | 25.92%Excellent 25.92% Excellent | 10.27%Good 10.27% Good | 1.17% |
Mankind Pharma LtdMankind Pharma ... MANKIND • 543904 | 50.6/100 | ₹2320.20₹2320 | ₹92012.53₹92012.53 | 52.62Average 52.6 Average | 14.68%Average 14.68% Average | 15.98%Good 15.98% Good | 0.55Good 0.6 Good | 11.73%Good 11.73% Good | 15.79%Excellent 15.79% Excellent | 0.04% |
Aurobindo Pharma LtdAurobindo Pharm... AUROPHARMA • 524804 | 28.8/100 | ₹1433.70₹1434 | ₹70798.69₹70798.69 | 20.69Average 20.7 Average | 11.08%Average 11.08% Average | 14.18%Average 14.18% Average | 0.22Excellent 0.2 Excellent | 3.87%Average 3.87% Average | 6.55%Good 6.55% Good | 0.33% |
Alkem Laboratories LtdAlkem Laborator... ALKEM • 539523 | 59.5/100 | ₹5314.50₹5315 | ₹67075.29₹67075.29 | 28.54Average 28.5 Average | 19.39%Good 19.39% Good | 20.38%Excellent 20.38% Excellent | 0.18Excellent 0.2 Excellent | 13.93%Good 13.93% Good | 9.21%Good 9.21% Good | 0.80% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Sun Pharmaceutical Industries Ltd share price433738.68 Cr
- Divis Laboratories Ltd share price170445.88 Cr
- Torrent Pharmaceuticals Ltd share price126430.62 Cr
- Cipla Ltd share price123059.76 Cr
- Dr Reddys Laboratories Ltd share price105224.96 Cr
Decipher Labs Ltd Quarterly Performance
Latest quarterly metrics for DECIPHER — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
-26.58%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
101.50%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
-1.18%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
-25.06%
Compounded annual net profit growth over 5 years
Decipher Labs Ltd Technical Indicators
SMA 50, SMA 200, RSI and volume signals for DECIPHER — calculated from daily price history
Momentum is balanced — neither overbought nor oversold.
Technical indicators are for educational purposes only. Not investment advice.
Decipher Labs Ltd Financial Statements
Annual income statement, balance sheet and cash flow for Decipher Labs Ltd (DECIPHER) — sourced from NSE/BSE filings.
Loading Financial Statements...
Fetching financial data for Decipher Labs Ltd
About DECIPHER (Decipher Labs Ltd)
Decipher Labs Ltd is a dynamic pharmaceutical company dedicated to unraveling complex health challenges through innovative drug development and strategic partnerships. With a focus... on both domestic and international markets, DECIPHER strives to deliver high-quality pharmaceutical solutions that improve patient outcomes. The company's research and development efforts are geared towards identifying novel therapeutic targets and formulating effective treatments for a wide range of diseases. DECIPHER is committed to maintaining the highest standards of quality and regulatory compliance across all its operations, from drug discovery to manufacturing and distribution. Beyond pharmaceuticals, DECIPHER also leverages its expertise in technology to offer specialized IT solutions, fostering synergy between healthcare and technological advancements. At the core of DECIPHER's operations are two key divisions: Pharmaceutical and Consultancy. The Pharmaceutical division is responsible for the development, manufacturing, and commercialization of a diverse portfolio of pharmaceutical products, including branded formulations, finished drugs, and essential chemical compounds. The Consultancy division provides comprehensive IT services tailored to the needs of the healthcare industry, offering technology integration, systems consulting, and software development expertise. By combining its pharmaceutical capabilities with its technological prowess, DECIPHER aims to revolutionize healthcare delivery and improve access to innovative treatments for patients worldwide. Decipher Labs Ltd is driven by a team of experienced scientists, healthcare professionals, and technology experts who are passionate about making a positive impact on global health. The company's commitment to research and development, coupled with its dedication to ethical business practices, positions it as a trusted partner in the pharmaceutical industry. DECIPHER's unwavering focus on innovation, quality, and customer satisfaction ensures that it remains at the forefront of pharmaceutical advancements, while its commitment to corporate social responsibility drives it to contribute to the well-being of communities around the world.
Company Details
Key Leadership
Latest News
DECIPHER Share Price: Frequently Asked Questions
What is the current share price of Decipher Labs Ltd?
Decipher Labs Ltd (DECIPHER) trades at ₹7.50 on NSE and BSE. Market cap ₹10.41 (Cr). Educational data only.
What is the P/E ratio of Decipher Labs Ltd?
Decipher Labs Ltd has a P/E of N/Ax vs industry average 31.77x.
What is the Bull Run score for Decipher Labs Ltd?
Decipher Labs Ltd has a Bull Run score of 9/100 based on 25+ financial parameters.
Does Decipher Labs Ltd pay dividends?
Decipher Labs Ltd has a dividend yield of 0.00%. Past dividends don't guarantee future payments.
What is the ROE of Decipher Labs Ltd?
Decipher Labs Ltd has ROE of 1.16%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Decipher Labs Ltd?
Decipher Labs Ltd has debt-to-equity of 0.02.
Is Decipher Labs Ltd a good investment?
Bull Run gives Decipher Labs Ltd a score of 9/100. This is not investment advice — consult a SEBI-registered advisor.